"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Descriptor ID |
D017239
|
MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 12 | 3 | 15 |
1995 | 17 | 3 | 20 |
1996 | 13 | 10 | 23 |
1997 | 24 | 10 | 34 |
1998 | 21 | 13 | 34 |
1999 | 18 | 11 | 29 |
2000 | 22 | 8 | 30 |
2001 | 20 | 17 | 37 |
2002 | 25 | 15 | 40 |
2003 | 26 | 16 | 42 |
2004 | 24 | 20 | 44 |
2005 | 20 | 23 | 43 |
2006 | 14 | 22 | 36 |
2007 | 15 | 14 | 29 |
2008 | 10 | 13 | 23 |
2009 | 17 | 23 | 40 |
2010 | 17 | 22 | 39 |
2011 | 18 | 26 | 44 |
2012 | 10 | 22 | 32 |
2013 | 12 | 18 | 30 |
2014 | 13 | 20 | 33 |
2015 | 14 | 25 | 39 |
2016 | 11 | 16 | 27 |
2017 | 8 | 19 | 27 |
2018 | 12 | 12 | 24 |
2019 | 13 | 25 | 38 |
2020 | 10 | 20 | 30 |
2021 | 4 | 20 | 24 |
2022 | 3 | 19 | 22 |
2023 | 3 | 15 | 18 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer. Breast Cancer Res. 2024 01 31; 26(1):20.
-
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial. Eur J Cancer. 2024 Mar; 200:113580.
-
Bardoxolone Methyl Ameliorates Chemotherapy-Induced Neuropathic Pain by Activation of Phosphorylated Nuclear Factor Erythroid 2-Related Factor 2 in the Dorsal Root Ganglia. Anesth Analg. 2024 Mar 01; 138(3):664-675.
-
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2024 Jan 20; 42(3):283-299.
-
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma. Cancer Res. 2023 10 02; 83(19):3184-3191.
-
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 10 07; 402(10409):1272-1281.
-
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6558-6566.
-
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform. Oncologist. 2023 06 02; 28(6):553-e472.
-
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. JAMA Oncol. 2023 06 01; 9(6):835-840.